Compare Cadila Healthcare with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs STRIDES PHARMA SCIENCE - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE STRIDES PHARMA SCIENCE CADILA HEALTHCARE/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 28.8 21.9 131.5% View Chart
P/BV x 4.6 2.1 225.8% View Chart
Dividend Yield % 0.7 0.2 314.7%  

Financials

 CADILA HEALTHCARE   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
STRIDES PHARMA SCIENCE
Mar-18
CADILA HEALTHCARE/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3521,147 30.7%   
Low Rs207642 32.2%   
Sales per share (Unadj.) Rs139.2317.2 43.9%  
Earnings per share (Unadj.) Rs11.87.8 150.0%  
Cash flow per share (Unadj.) Rs18.625.1 74.1%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %1.30.2 560.3%  
Book value per share (Unadj.) Rs101.4274.3 37.0%  
Shares outstanding (eoy) m1,023.7489.50 1,143.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.02.8 71.2%   
Avg P/E ratio x23.7114.0 20.8%  
P/CF ratio (eoy) x15.035.7 42.1%  
Price / Book Value ratio x2.83.3 84.5%  
Dividend payout %29.825.5 116.7%   
Avg Mkt Cap Rs m286,03380,058 357.3%   
No. of employees `00013.42.5 534.7%   
Total wages/salary Rs m24,1454,341 556.3%   
Avg. sales/employee Rs Th10,632.711,325.8 93.9%   
Avg. wages/employee Rs Th1,801.21,731.4 104.0%   
Avg. net profit/employee Rs Th898.5280.1 320.8%   
INCOME DATA
Net Sales Rs m142,53128,394 502.0%  
Other income Rs m1,139941 121.1%   
Total revenues Rs m143,67029,334 489.8%   
Gross profit Rs m24,1983,965 610.2%  
Depreciation Rs m6,9651,540 452.2%   
Interest Rs m3,4181,962 174.2%   
Profit before tax Rs m14,9541,403 1,065.7%   
Minority Interest Rs m2880-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m3,19897 3,286.7%   
Profit after tax Rs m12,044702 1,715.4%  
Gross profit margin %17.014.0 121.6%  
Effective tax rate %21.46.9 308.4%   
Net profit margin %8.52.5 341.7%  
BALANCE SHEET DATA
Current assets Rs m87,15424,836 350.9%   
Current liabilities Rs m82,69418,993 435.4%   
Net working cap to sales %3.120.6 15.2%  
Current ratio x1.11.3 80.6%  
Inventory Days Days7171 100.6%  
Debtors Days Days94113 82.7%  
Net fixed assets Rs m133,23634,289 388.6%   
Share capital Rs m1,024895 114.4%   
"Free" reserves Rs m102,73323,651 434.4%   
Net worth Rs m103,75724,546 422.7%   
Long term debt Rs m32,14615,513 207.2%   
Total assets Rs m236,86665,437 362.0%  
Interest coverage x5.41.7 313.4%   
Debt to equity ratio x0.30.6 49.0%  
Sales to assets ratio x0.60.4 138.7%   
Return on assets %6.54.1 160.3%  
Return on equity %11.62.9 405.8%  
Return on capital %13.76.9 199.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75215,697 336.1%   
Fx outflow Rs m14,504735 1,972.3%   
Net fx Rs m38,24814,962 255.6%   
CASH FLOW
From Operations Rs m25,0541,871 1,339.3%  
From Investments Rs m-10,1235,826 -173.8%  
From Financial Activity Rs m-10,942-10,157 107.7%  
Net Cashflow Rs m3,989-2,615 -152.5%  

Share Holding

Indian Promoters % 74.8 27.7 270.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 37.8 22.0%  
FIIs % 5.9 8.6 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 25.9 42.5%  
Shareholders   44,069 56,241 78.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  UNICHEM LAB  ORCHID PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Up 126 Points; Indicates Gap-Up Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a positive note today. At 8:10 am, it was trading up by 126 points, or 0.87% higher at 14,480 levels.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 25, 2021 09:14 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS